Interim report for the period January 1 – September 30, 2024
Reading Time: 5 minutes Strengthened financial position and increased production paceIn the third quarter of 2024, Cinis Fertilizer delivered its first shipload of potassium sulfate to customer Van Iperen International, who in turn resold it to growers in approximately 25 countries worldwide. After the end of
Akiram Therapeutics to Showcase Key Data on AKIR001 at Targeted Radiopharmaceuticals Summit Europe 2024
Reading Time: 3 minutes Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, will present breakthrough IND-enabling preclinical data on its drug candidate 177Lu-AKIR001 and the design of its first-in-human clinical trial at the Targeted Radiopharmaceuticals Summit Europe 2024 in Amsterdam, December 3-5. The data
Keturah Announces Campaign for Its Developments, Introduces 5-Year Post-Handover Plan
Reading Time: 2 minutes Dubai, United Arab Emirates: Keturah, the revolutionary global luxury wellbeing real estate and hospitality concept has announced the launch of a sales campaign for The Ritz-Carlton Residences, Dubai, Creekside—part of the Keturah Resort—and Keturah Reserve which runs until 30 December.
Kesko Corporation: Disclosure in compliance with Chapter 9, Section 10 of the Finnish Securities Markets Act (26.11.2024)
Reading Time: 2 minutes Kesko Corporation has on 27 November 2024 received a notification pursuant to Chapter 9, Section 5 of the Finnish Securities Markets Act from BlackRock, Inc. According to the notification, on 26 November 2024, BlackRock, Inc.’s holding in Kesko Corporation exceeded the
Leqembi[®] launched in South Korea
Reading Time: 4 minutes Stockholm, Sweden, November 28, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced today that Leqembi® (generic name: lecanemab) has been launched in South Korea. Leqembi received approval in South Korea in May 2024 for treatment in adult
Inside information: Bioretec Ltd successfully completes private placement raising EUR 6 million
Reading Time: 7 minutes Bioretec Ltd Inside information 27 November 2024 at 10.15 p.m. EET THE INFORMATION CONTAINED IN THIS RELEASE IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA OR THE UNITED STATES OR IN
Inside information: Bioretec Ltd launches an accelerated book-building process to raise approximately EUR 5 million through a private placement of new shares
Reading Time: 8 minutes Bioretec Ltd Inside information 27 November 2024 at 6:30 p.m. EET THE INFORMATION CONTAINED IN THIS RELEASE IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA OR THE UNITED STATES OR IN
Gentoo Media – Mandatory notification of trade
Reading Time: < 1 minute MJ Foundation Fundacja Rodzinna, a company related to Mateusz Juroszek, Board Member and primary insider of Gentoo Media Inc. (Gentoo) has today acquired 129 shares in Gentoo at a price of SEK 24.30 per share. After this transaction, close associates
FISKARS CORPORATION: ACQUISITION OF OWN SHARES 27.11.2024
Reading Time: < 1 minute Stock Exchange Release 27.11.2024 at 18:30 EET/EEST FISKARS CORPORATION: ACQUISITION OF OWN SHARES 27.11.2024 Date 27.11.2024 Exchange transaction Buy Share class FSKRS Amount 1,305 Average price/share 14.7103 EUR Highest price/share 14.7800 EUR Lowest price/share
Buybacks of shares by H&M during week 48, 2024. The share buyback programme is now complete and has been closed.
Reading Time: 2 minutes Between 25 November 2024 and 26 November 2024 H & M Hennes & Mauritz AB (publ) (LEI code 529900O5RR7R39FRDM42) has repurchased in total 303 692 own B shares (ISIN: SE0000106270) as part of the share buyback programme initiated by the board